Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar;8(1):23-7.
doi: 10.1007/s11914-010-0005-4.

Anabolic therapies

Nancy E Lane  1 , Stuart L Silverman
Affiliations

Anabolic therapies

Nancy E Lane et al. Curr Osteoporos Rep. 2010 Mar.

Abstract

The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. Recombinant human parathyroid hormone (rhPTH) (1-34) is the first US Food and Drug Administration-approved anabolic therapy. Its use has been limited by the need for subcutaneous injection. Newer delivery systems include transdermal and oral preparations. Newer anabolic therapies include monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis; and use of bone morphogenetic proteins and parathyroid hormone-related protein PTHrP, a calcium-regulating hormone similar to PTH.

PubMed Disclaimer

References

    1. van Amerongen R, Nusse R. Towards an integrated view of Wnt signaling in development. Development. 2009;136:3205–3214. doi: 10.1242/dev.033910. - DOI - PubMed
    1. Hoeppner LH, Secreto FJ, Westendorf JJ. Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets. 2009;13:455–496. doi: 10.1517/14728220902841961. - DOI - PMC - PubMed
    1. Kneissel M. The promise of sclerostin inhibition for the treatment of osteoporosis. IBMS BoneKEy. 2009;6:259–264. doi: 10.1138/20090388. - DOI
    1. Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerostin is due to the deficiency of a novel secreted protein (SOST) Hum Mol Genet. 2001;10:537–543. doi: 10.1093/hmg/10.5.537. - DOI - PubMed
    1. Wengenroth M, Vasvari G, Federspil PA, et al. Case 150: Van Buchem disease (hyperostosis corticalis generalisata). Radiology 209;253:272–76. - PubMed

MeSH terms